# Dasatinib Holiday for Improved Tolerability

> **NCT02890784** · PHASE3 · COMPLETED · sponsor: **University of Jena** · enrollment: 291 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic

## Interventions

- **DRUG:** dasatinib (SPRYCEL®)

## Key facts

- **NCT ID:** NCT02890784
- **Lead sponsor:** University of Jena
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2023-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890784, "Dasatinib Holiday for Improved Tolerability". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02890784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*